A team at the University of Pennsylvania’s Abramson Cancer Center and the Perelman School of Medicine reported that 27 out of 29 patients with an advanced blood cancer saw their cancers go into remission or disappear altogether when they received genetically modified T-cells that targeted and destroyed the tumor cells.
Weizmann Institute Professor Zelig Eshhar was one of the first to work on the innovative immunotherapy technique. He said, “In our lab, we cured many rats and mice of cancer. I have been saying for years that we could do this in people, as well.”
Eshhar has been conducting T-cell research for over a decade and laid out the mechanics of T-cell immunotherapy. He cautioned that the breakthrough did not represent a “cure for cancer” since “you have to develop specific T-cells for each kind of cancer.”